Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome

PHASE3CompletedINTERVENTIONAL

Enrollment

209

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

July 12, 2018

Study Completion Date

July 12, 2018

Conditions

Dry Eye Syndrome

Interventions

DRUG

HU007

cyclosporine 0.02%, trehalose 3%

DRUG

Restasis

cyclosporine 0.05%

DRUG

Moisview

trehalose 3%

Trial Locations (1)

Seoul ST.Mary's Hospital, Seoul

All Listed Sponsors

lead

Huons Co., Ltd.

INDUSTRY

NCT03461575 - Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome | Biotech Hunter | Biotech Hunter